Close Menu

DARPA

The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.

The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.

The company will use the funds to work in collaboration with George Mason University to apply its technology to detecting viruses in non-invasive samples.